Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q1 2024 Earnings Presentation
12 slides from Apellis Pharmaceuticals's earnings presentation, May 7, 2024
Slide 1: First Quarter 2024 Financial Results Conference Call
First Quarter 2024 Financial Results Conference Call May 7, 2024
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Operating Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 4: Strong start to 2024
Strong start to 2024 On track to become multi-billion-dollar U.S. product Transforming SOC for patients with PNH ✓ ~$137.5M in 1Q 2024 U.S. net product revenue, a ✓ ~$25.6M in 1Q 2024 U.S. net product revenue 20% increase QoQ ✓ 97% compliance rate ✓ ~250,000 injections estimated through March 2024 (
Slide 5: SYFOVRE is #1 chosen GA treatment in the U.S.
SYFOVRE is #1 chosen GA treatment in the U.S. ✓ ~77k SYFOVRE doses delivered to ECPs in 1Q 20241 ✓ ~250k SYFOVRE injections estimated to have been administered as of March 2024 (incl. clinical trials)2 ✓ Double-digit number of new sites each week1 ✓ Estimated rate of vasculitis remains rare at appro
Slide 6: GA market opportunity is large and growing
GA market opportunity is large and growing Up to 1.5M GA patients estimated in U.S. GA patients currently diagnosed and in ECP office Treated GA patients (as of March 2024) 6
Slide 7: Executing the next stage of SYFOVRE commercial strategy
Executing the next stage of SYFOVRE commercial strategy PHYSICIANS PATIENTS ✓ Increase reach within existing ECP target users ✓ Expand use among those ECP targets who have not used SYFOVRE yet ✓ Further educate other referring eyecare providers Now Launched! SYFOVRE Branded Direct-to-Consumer Patien
Slide 8: EMPAVELI continues to elevate the standard of care in PNH
EMPAVELI continues to elevate the standard of care in PNH As of March 31, 2024: • $25.6 million in 1Q 2024 U.S. net product sales • ~97% patient compliance rate • Continued strong safety profile, with zero cases of meningococcal infection and low thrombosis rates ASHLEY Living with PNH 8
Slide 9: C3G and IC-MPGN: two debilitating kidney diseases
C3G and IC-MPGN: two debilitating kidney diseases • Rare kidney diseases with no approved therapies • Progress to kidney failure in ~50% of patients within 5-10 years of diagnosis ‒ Leads to kidney transplant or lifelong dialysis, neither curative Chase Living with C3G • ~5,0001 people with C3G/IC-M
Slide 10: VALIANT Phase 3 study: top-line data expected mid-2024
VALIANT Phase 3 study: top-line data expected mid-2024 Primary endpoint readout Up to 10 weeks 26 weeks 26 weeks 8 weeks Population: Patients 12 Screening Randomized, double-blind Open-label period Follow-up* years+ with C3G or primary placebo-controlled period IC-MPGN pre- and post- transplant and
Slide 11: Consolidated first quarter 2024 financial results
Consolidated first quarter 2024 financial results (In USD Millions) Three Months Ended March 31, 2024 2023 EMPAVELI U.S. Net Product Sales $25.6 $20.4 SYFOVRE U.S. Net Product Sales $137.5 $18.4 Licensing and Other Revenue $9.3 $6.0 Total Revenue $172.3 $44.8 Cost of Sales $20.2 $7.8 Expenses R&D Ex
Slide 12: First Quarter 2024 Financial Results Conference Call
First Quarter 2024 Financial Results Conference Call May 7, 2024
Apellis Pharmaceuticals — Q1 2024 Earnings Presentation on 6ix